MENLO PARK, Calif.--(BUSINESS WIRE)--iScience Interventional (iScience, Menlo Park, CA), pioneers of site-specific therapies for anterior and posterior ocular diseases, today announced it has signed a clinical and commercial supply agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD) and its affiliates. In this agreement, iScience will supply iTrack 275 microcatheters for the delivery of J&JPRD’s cell therapy, CNTO2476, which is currently in clinical trials for the treatment of retinal degeneration.
“We are very pleased to continue our relationship in this particular area,” stated Michael F. Nash, President & CEO of iScience Interventional. “Site-specific access to the locations where retinal diseases occur is changing how pharmaceutical and biotechnology companies are looking at development of new treatment therapies. With devices the size of several human hairs we can now administer biologics and pharmaceuticals to virtually any location within the eye.”
According to Mike Samuel, MD, clinical investigator with the iTrack 275, “The opportunity to preserve and potentially restore failing cells is becoming a growing reality in ophthalmology. We are witnessing the simultaneous convergence of several significant technological advancements in devices and biologics.”
Dr. Allen C. Ho, Professor of Ophthalmology and vitreoretinal surgeon at Mid Atlantic Retina and Wills Eye Hospital added, “Site-specific access with the ability to deliver therapies to the subretinal space adjacent to diseased retinal pigment epithelium and retinal photoreceptors - without a vitrectomy or retinotomy - is an exciting new breakthrough for delivery of novel therapies, for example, stem cell treatments.”
The terms of this non-exclusive agreement were not disclosed.
About iScience Interventional
iScience Interventional, based in Menlo Park, California and founded in 1999, is a science and technology company that specializes in the development of leading-edge, interventional therapies and procedures for the eye. Breakthrough interventional systems are enabling a new generation of site specific treatments for several of the most significant sight-threatening diseases in ophthalmology.